| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW |
Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Rd, London. SW3 6JJ, UK
(Requests for offprints should be addressed to M Dowsett; Email: mitch{at}icr.ac.uk)
The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clinical problem. The target of tamoxifen in vivo is the ER. Over the last decade many advances have been made in our understanding of the biology of the ER which may help to explain how resistance to tamoxifen develops. Such mechanisms may include changes in the expression of ER
or ERß, alterations in co-regulatory proteins, and the influences of cellular kinase signal transduction pathways. The experimental and clinical evidence supporting these mechanisms of tamoxifen resistance are discussed in this review.
This article has been cited by other articles:
|
|
 |
|
  S. Masri, S. Phung, X. Wang, X. Wu, Y.-C. Yuan, L. Wagman, and S. Chen Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen Receptor Cancer Res., June 15, 2008; 68(12): 4910 - 4918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Devalapally, Z. Duan, M. V. Seiden, and M. M. Amiji Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles Clin. Cancer Res., May 15, 2008; 14(10): 3193 - 3203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dowsett Factors Predicting Response and Resistance to Endocrine Therapy of Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 14 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wu, D. R. Soler, M. C. Abba, M. I. Nunez, R. Baer, C. Hatzis, A. Llombart-Cussac, A. Llombart-Bosch, and C. M. Aldaz CtIP Silencing as a Novel Mechanism of Tamoxifen Resistance in Breast Cancer Mol. Cancer Res., December 1, 2007; 5(12): 1285 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Schroth, L. Antoniadou, P. Fritz, M. Schwab, T. Muerdter, U. M. Zanger, W. Simon, M. Eichelbaum, and H. Brauch Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes J. Clin. Oncol., November 20, 2007; 25(33): 5187 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J W Assender, J M W Gee, I Lewis, I O Ellis, J F R Robertson, and R I Nicholson Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer J. Clin. Pathol., November 1, 2007; 60(11): 1216 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jiang, N. Sarwar, D. Peston, E. Kulinskaya, S. Shousha, R. C. Coombes, and S. Ali Phosphorylation of Estrogen Receptor-{alpha} at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients Clin. Cancer Res., October 1, 2007; 13(19): 5769 - 5776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schrecengost, R. B. Riggins, K. S. Thomas, M. S. Guerrero, and A. H. Bouton Breast Cancer Antiestrogen Resistance-3 Expression Regulates Breast Cancer Cell Migration through Promotion of p130Cas Membrane Localization and Membrane Ruffling Cancer Res., July 1, 2007; 67(13): 6174 - 6182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Kilker and M. D. Planas-Silva Cyclin D1 Is Necessary for Tamoxifen-Induced Cell Cycle Progression in Human Breast Cancer Cells Cancer Res., December 1, 2006; 66(23): 11478 - 11484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Massarweh and R. Schiff Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S15 - S24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hiscox, L Morgan, T. Green, and R. I Nicholson Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Sarwar, J-S Kim, J Jiang, D Peston, H D Sinnett, P Madden, J M Gee, R I Nicholson, A E Lykkesfeldt, S Shousha, et al. Phosphorylation of ER{alpha} at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER{alpha} phosphorylation in breast cancer progression. Endocr. Relat. Cancer, September 1, 2006; 13(3): 851 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T M Sadler, M Gavriil, T Annable, P Frost, L M Greenberger, and Y Zhang Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer, September 1, 2006; 13(3): 863 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Holm, S. Rayala, K. Jirstrom, O. Stal, R. Kumar, and G. Landberg Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst, May 17, 2006; 98(10): 671 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J S Reis-Filho, C Westbury, and J-Y Pierga The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Farooqui, Z. H. Geng, E. J. Stephenson, N. Zaveri, D. Yee, and K. Gupta Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol. Cancer Ther., March 1, 2006; 5(3): 611 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Acconcia, C. J. Barnes, and R. Kumar Estrogen and Tamoxifen Induce Cytoskeletal Remodeling and Migration in Endometrial Cancer Cells Endocrinology, March 1, 2006; 147(3): 1203 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S C J P Gielen, L C M Kuhne, P C Ewing, L J Blok, and C W Burger Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study Endocr. Relat. Cancer, December 1, 2005; 12(4): 1037 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kishimoto, Z. Wang, P. Bhat-Nakshatri, D. Chang, R. Clarke, and H. Nakshatri The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1{alpha}/CXCL12 Carcinogenesis, October 1, 2005; 26(10): 1706 - 1715. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
